Retatrutide 20 mg is a high-purity, lyophilised synthetic research compound supplied for laboratory research only. It is an investigational triple-agonist research compound that targets the GLP-1, GIP and glucagon receptors, and it is studied in metabolic research models.
Key Characteristics:
- Research use only: Supplied for scientific and laboratory research. Not for human consumption.
- Mechanism of interest: Simultaneous agonism of the GLP-1, GIP and glucagon receptors.
- Format: Lyophilised (freeze-dried) powder, 20 mg per vial.
- Quality: Supplied with batch testing data and certificate of analysis (COA) information.
The Science Behind Triple-Agonist Signalling
GLP-1 receptor: GLP-1 is an incretin hormone involved in appetite signalling, gastric emptying and post-meal glucose handling. It is widely used as a reference pathway in metabolic research.
GIP receptor: GIP is an incretin hormone that influences insulin secretion and adipose tissue metabolism in laboratory models.
Glucagon receptor: Glucagon signalling is studied for its role in energy expenditure, hepatic lipid metabolism and substrate oxidation.
Because it engages all three pathways, retatrutide is a subject of interest in research comparing single-, dual- and triple-agonist mechanisms. It is an investigational compound and is not approved for therapeutic use in Australia. Nothing on this page should be read as a claim about safety or efficacy in humans.
Storage
Store the lyophilised powder at -20°C. Once reconstituted with bacteriostatic water under aseptic laboratory conditions, store at 2°C to 8°C and protect from light.
For laboratory and research purposes only. Not for human consumption, medical use, or veterinary use.
